Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ROS1 rearrange |
| Therapy | Taletrectinib |
| Indication/Tumor Type | lung non-small cell carcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ROS1 rearrange | lung non-small cell carcinoma | sensitive | Taletrectinib | Guideline | Actionable | Ibtrozi (taletrectinib) is included in guidelines as preferred first-line or subsequent therapy for patients with advanced or metastatic non-small cell lung cancer harboring a ROS1 rearrangement (NCCN.org). | detail... |
| ROS1 rearrange | lung non-small cell carcinoma | sensitive | Taletrectinib | FDA approved - On Companion Diagnostic | Actionable | In a Phase II trial (TRUST-II) that supported FDA approval, Ibtrozi (taletrectinib) treatment demonstrated safety in non-small cell lung cancer patients with ROS1 rearrangement and resulted in a confirmed investigator-assessed objective response rate (cORRinv) of 94% (17/18) and a disease control rate (DCR) of 100% in the treatment-naive cohort and a cORRinv of 55% (12/22) and DCR of 91% in the previously treated cohort (Ann Oncol (2023) 34 (suppl_2):S788-S789; NCT04919811). | detail... detail... |
| ROS1 rearrange | lung non-small cell carcinoma | sensitive | Taletrectinib | FDA approved - On Companion Diagnostic | Actionable | In a Phase II trial (TRUST-I) that supported FDA approval, Ibtrozi (taletrectinib) therapy resulted in a 90.6% (96/106) overall response rate (ORR) and 95.3% disease control rate (DCR) in TKI-naive non-small cell lung cancer patients with ROS1 rearrangement and 51.5% (34/66) ORR and 83.3% DCR in pretreated patients, intracranial ORR of 87.5% (7/8) and DCR of 100% in patients with baseline brain lesions, and partial responses in 8 of 12 patients with secondary ROS1 G2032R (PMID: 38822758; NCT04395677). | detail... 38822758 |
| ROS1 rearrange | lung non-small cell carcinoma | sensitive | Taletrectinib | Phase I | Actionable | In a Phase I trial, Ibtrozi (taletrectinib) demonstrated manageable toxicity, resulted in an objective response rate of 33.3% (2/6) in patients with advanced non-small cell lung cancer harboring ROS1 rearrangements (PMID: 32591465). | 32591465 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| NCCN.org | Full reference... | |
| (32591465) | U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors. | Full reference... |
| 1373P Efficacy and safety of taletrectinib in patients (Pts) with ROS1+ non-small cell lung cancer (NSCLC): Interim analysis of global TRUST-II study | Full reference... | |
| (38822758) | Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lung Cancer: The Phase II TRUST-I Study. | Full reference... |
| Ibtrozi (taletrectinib) FDA Drug Label | Full reference... | |
| Ibtrozi (taletrectinib) FDA Drug Label | Full reference... |